ClinicalTrials.gov
public full text
Public Domain
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration. The present study is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal symptoms.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction#884398
- Prescription Opioid Discontinuation: Honoring Patient Insights and Experience to Support Safe and Caring Transitions -- Decision Aid Pilot#878831
- Effective Treatment for Prescription Opioid Abuse#862023
- The remaining role and feasibility of detoxification in opioid addiction after 30 years of medication for opioid use disorder#670147
- Aprepitant to Mitigate Opioids' Cognitive Side Effects#846475
Record · ID 839388
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive